Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Testosterone Replacement Therapy (TRT)
... 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. TRT Injectables, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.6 Billion by the ... Read More
-
Acute Heart Failure (AHF) Therapeutics
... Billion by 2030, growing at a CAGR of 21.0% over the analysis period 2024-2030. Cardiac Glycosides, one of the segments analyzed in the report, is expected to record a 21.5% CAGR and reach US$762.4 Million ... Read More
-
ADME-Toxicology Testing
... CAGR of 11.2% over the analysis period 2024-2030. Cell Culture, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$9.6 Billion by the end of the analysis ... Read More
-
Gynecological Cancer Drugs
... at a CAGR of 5.1% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$12.1 Billion by the end of ... Read More
-
Diabetic Macular Edema Treatment
... 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Anti-VEGF, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$2.7 Billion by the end ... Read More
-
Microbiome Therapeutics
... CAGR of 56.8% over the analysis period 2024-2030. C. Difficile Infection, one of the segments analyzed in the report, is expected to record a 53.0% CAGR and reach US$7.3 Billion by the end of the ... Read More
-
Myasthenia Gravis Drugs
... at a CAGR of 6.6% over the analysis period 2024-2030. Drug Treatment, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of ... Read More
-
Oligonucleotide Therapeutics
... CAGR of 8.7% over the analysis period 2024-2030. Antisense / RNAI Oligonucleotides, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$4.0 Billion by the end of ... Read More
-
Post-Traumatic Stress Disorder (PTSD) Therapeutics
... Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$2.1 Billion by ... Read More
-
Leukemia Therapeutics
... CAGR of 5.6% over the analysis period 2024-2030. Chronic Myeloid Leukemia, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$9.1 Billion by the end of the ... Read More
-
Lupus Therapeutics
... CAGR of 8.7% over the analysis period 2024-2030. Anti-Inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$2.7 Billion by the end of the analysis ... Read More
-
Cushing`s Syndrome Diagnostics and Treatment
... Million by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Cushing`s Syndrome Treatment, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$473.9 ... Read More
-
Krabbe Disease Treatment
... at a CAGR of 6.2% over the analysis period 2024-2030. Anticonvulsants, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$823.5 Million by the end of the ... Read More
-
Protein Therapeutics
... CAGR of 5.8% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$284.7 Billion by the end of the analysis ... Read More
-
Amyotrophic Lateral Sclerosis
... at a CAGR of 19.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$345.9 Million While China is Forecast to Grow at 18.4% CAGR The Amyotrophic Lateral Sclerosis market in the U.S. ... Read More
-
Idiopathic Pulmonary Fibrosis
... at a CAGR of 5.7% over the analysis period 2024-2030. Pirfenidone, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$4.8 Billion by the end of the ... Read More
-
Cancer Supportive Care Drugs Global Market Report 2025
... care drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain a truly ... Read More
-
Liver Cirrhosis - Market Insight, Epidemiology, and Market Forecast - 2034
... is a chronic and progressive liver disease characterized by the replacement of healthy liver tissue with scar tissue estimated to approximately 3,390 thousand diagnosed prevalent population in 2023 in the 7MM. Liver cirrhosis is a ... Read More
-
Bullous Keratopathy - Market Insights, Epidemiology, and Market Forecast - 2034
... Japan represented 13% and 9% of the cases, respectively. The bullous keratopathy market is set for steady growth, with a robust compound annual growth rate (CAGR) anticipated from 2024 to 2034. This expansion in the ... Read More
-
IgG4-Related Disease - Market Insight, Epidemiology, and Market Forecast - 2034
... recent discovery, lack of widespread recognition, and frequently indolent presentation, it is likely that it is underrecognized and underreported. There is a male predominance, and the average age at diagnosis in large cohorts is in ... Read More
-
Systemic Psoriasis Therapeutics
... at a CAGR of 8.1% over the analysis period 2024-2030. TNF Inhibitors, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$18.5 Billion by the end of ... Read More
-
Schizophrenia Therapeutics
... CAGR of 4.2% over the analysis period 2024-2030. Second Generation Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$7.7 Billion by the end of ... Read More
-
Systemic Lupus Erythematosus (Sle) Drugs
... Million by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$68.0 Million While China is Forecast to Grow at 6.1% CAGR The Systemic Lupus Erythematosus ... Read More
-
Focal Segmental Glomerulosclerosis
... at a CAGR of 6.6% over the analysis period 2024-2030. Primary, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$17.9 Billion by the end of the ... Read More
-
Chronic Myelogenous Leukemia Treatment
... 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Disease Specific Treatment, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$3.4 Billion by ... Read More
Research Assistance
